



## REPORT N°12

# ADVERSE EVENTS FOLLOWING IMMUNIZATION WITH COVID-19 VACCINES IN LEBANON

COVID-19 Vaccines - Lebanon

Prepared by:

**The Pharmacovigilance Team**

Ministry of Public Health and the Lebanese University  
Beirut, Lebanon

Team Lead:

**Karam Rita, Pharm D, PhD**

Senior Technical and Clinical Manager:

**Zeitoun Abeer, Pharm D, MS**

**February 14, 2021 – December 14, 2022**



# INDEX

**EXECUTIVE SUMMARY** Page 3

**BACKGROUND** Page 4

**HIGHLIGHTS** Page 4

**REPORTING OVERVIEW** Page 6

- a. *Global Analysis*
- b. *Demographics*
- c. *Non-Serious Adverse Events Following Immunization*
- d. *Serious Adverse Events Following Immunization*
- e. *Adverse Events Following Immunization in Pregnant Women*
- f. *Adverse Events Following Immunization in Children and Adolescents*
- g. *Safety Signals*

**DESCRIPTION OF SERIOUS ADVERSE EVENTS FOLLOWING IMMUNIZATION** Page 20

**COMPARISON OF AEFIS WITH COVID-19 VACCINES IN LEBANON WITH INTERNATIONAL DATA** Page 21

**CONCLUSION** Page 23

**TECHNICAL NOTES** Page 23


**CAVEAT** Page 25

**BIBLIOGRAPHY** Page 25

## EXECUTIVE SUMMARY

This executive summary provides an overview of Adverse Events Following Immunization (AEFIs) that were temporally associated (i.e., occurred after administration of the vaccine) to the five COVID-19 vaccines (Pfizer-BioNTech Vaccine, AstraZeneca Vaccine, Sputnik V Vaccine, Moderna Vaccine, and Sinopharm Vaccine) available in Lebanon during the mass campaign immunization between February 14<sup>th</sup>, 2021, and December 14<sup>th</sup>, 2022. According to the World Health Organization (WHO), an AEFI is any untoward medical occurrence that follows immunization and does not necessarily have a causal relationship with the vaccine. The adverse event may be any unfavorable or unintended sign, abnormal laboratory finding, symptom or disease.

The following information summarizes COVID-19 vaccines doses since their first deployment in Lebanon, from February 14<sup>th</sup>, 2021, until December 14<sup>th</sup>, 2022:



*As per the COVID-19 vaccination dashboard provided by IMPACT platform on December 14<sup>th</sup>, 2022*

*All percentages are calculated with respect to the total administered doses*

## BACKGROUND

Within the scope of the AEFI surveillance related to the available COVID-19 Vaccines in Lebanon, the Pharmacovigilance (PV) Program established a procedure for the management of reported AEFIs. Vaccine recipients experiencing any AEFI can report through one of the following means: 1214 Hotline Call Center, IMPACT Platform, Vaccination Sites/Hospital Sites through “Kobo Toolbox: AEFIs Software for reporting” or by direct contact with the PV program, and other sources including Preventive Medicine, Epidemiology Surveillance Program, Health Education, other departments from the Ministry of Public Health (MoPH) and the Marketing Authorization Holder (MAH). A case report refers to a report received by the PV Program which pertains to one individual vaccine recipient who reported at least one adverse event after receiving the COVID-19 vaccine (i.e., temporally associated with the vaccine). All case reports are screened and validated for data completion. Incomplete or inconsistent case reports are followed-up directly with the initial reporter. The case reports are classified as serious or non-serious cases. The non-serious case reports are entered directly into the national web-based report management system, VigiFlow, while serious cases go through a follow-up/ investigation, causality assessment and validation by the Serious AEFI Special Committee before they are entered into VigiFlow. The surveillance aims to establish a rigorous safety profile regarding the COVID-19 vaccines administered in Lebanon.

## HIGHLIGHTS

- A total of 7,188 case reports and 25,841 AEFIs were received following the administration of 5,602,239 doses of COVID-19 vaccines (Pfizer-BioNTech, AstraZeneca, Sputnik V, Moderna, and Sinopharm) in Lebanon between the 14<sup>th</sup> of February 2021 and the 14<sup>th</sup> of December 2022:
  - This is equivalent to a reporting rate of 1.28 case reports and 4.61 AEFIs per 1,000 doses administered
  - This represents an increase of 159 case reports and 357 AEFIs in comparison with the previous report dated from February 14<sup>th</sup>, 2021 to June 30<sup>th</sup>, 2022
  - The age group of vaccine recipients who mostly reported AEFIs was between 18 and 44 years old (54.5%), with females reporting more than males (61.0% vs. 39%) (Table 5)
  - Most of the reporters were vaccine recipients (83.0%) (Table 6)
- The 7,188 case reports were received through one of the following means (Table 1):
  - IMPACT Platform: 3,866 case reports (53.8%)
  - 1214 Hotline Call Center: 2,138 case reports (29.7%)
  - Vaccination Sites/Hospital Sites through “Kobo toolbox: AEFIs Software for reporting” or by direct contact with the PV program: 955 case reports (13.3%)
  - Marketing Authorization Holder (MAH): 159 case reports (2.2%)
  - Other reporting sources which may include Preventive Medicine, Epidemiology Surveillance Program, Health Education, and other departments from the MoPH: 70 case reports (1.0%)

- Out of the 7,188 case reports (Table 2):
  - 5,339 case reports were associated with dose 1 of vaccination (74.28%)
  - 1,452 case reports were associated with dose 2 of vaccination (20.20%)
  - 303 case reports were associated with dose 3 of vaccination (4.22%)
  - 7 case reports were associated with dose 4 of vaccination (0.10%)
  - 87 case reports were missing this information (1.21%)
  
- The 7,188 case reports were received from 8 governorates in Lebanon (Mount Lebanon, Beirut, North Lebanon, Bekaa, South Lebanon, Nabatiyeh, Akkar, and Baalbeck-Hermel). Out of the 7,188 case reports (Table 3):
  - 2,907 (40.45%) were from Mount Lebanon
  - 2,078 (28.91%) were from Beirut
  - 732 (10.18%) were from North Lebanon
  - 406 (5.64%) were from South Lebanon
  - 253 (3.51%) were from Bekaa
  - 213 (2.96%) were from Nabatiyeh
  - 143 (2.0%) were from Akkar
  - 97 (1.35%) were from Baalbeck-Hermel
  - 359 (5.0%) were missing this information
  
- Out of the 7,188 case reports (Figure 3, Table 4):
  - 6,654 case reports were non-serious (92.6% of total case reports)
  - 534 case reports included serious AEFIs (7.4% of total case reports) as per the WHO definition (refer to Technical Notes for serious cases definition as per WHO), out of which:
    - o 391 case reports included serious AEFIs that did not require hospitalization nor lead to death. These were identified as other medically important events (5.44% of total case reports)
    - o 143 case reports resulted in either hospital admission or death representing 1.98% of all case reports and a reporting rate of 0.026 per 1,000 doses of vaccines
  
- Of the total received AEFIs, the most reported AEFIs by System Organ Class (SOC) with the five COVID-19 vaccines available in Lebanon were (Table 13):
  - General Disorders and Administration Site Conditions (82.1% of total reported AEFIs per SOC)
  - Nervous System Disorders (44.6% of total reported AEFIs per SOC)
  - Gastrointestinal Disorders (25.9% of total reported AEFIs per SOC)
  
- Of the total received non serious AEFIs (6,654 case reports), the 5 most frequently reported AEFIs with the five COVID-19 vaccines available in Lebanon were (Table 7):
  - Injection site pain (39.2%)
  - Fatigue (38.2%)
  - General pain which may correspond to body pain or joint pain (37.3%)
  - Headache (34.6%)
  - Pyrexia (31.0%)
  
- The most frequently reported non-serious AEFIs per vaccine were (Table 8, 9, 10, 11 and 12):
  - Injection site pain following the Pfizer-BioNTech Vaccine (35.5% of total reported AEFIs).
  - Fatigue following the AstraZeneca Vaccine (56.2% of the total reported AEFIs), the Sputnik V Vaccine (66.4% of the total reported AEFIs), and the Sinopharm Vaccine (50.0% of the total reported AEFIs).
  - Pain following the Moderna Vaccine (37.0% of total reported AEFIs).

# REPORTING OVERVIEW

## a. Global Analysis

All data presented below will include AEFIs of case reports related to the five COVID-19 vaccines (Pfizer–BioNTech, AstraZeneca, Sputnik V, Moderna, and Sinopharm).

Table 1 summarizes the case reports by reporting means: 1214 Hotline Call Center, IMPACT Platform, Vaccination Sites/Hospital Sites through “Kobo toolbox: AEFIs Software for reporting”, Marketing Authorization Holder (MAH) or direct contact with the PV program, and other sources including Preventive Medicine Department, Epidemiology Surveillance Program, Health Education Program, and other departments from the MoPH.

**Table 1: Summary of case reports by means of reporting**

Means of Reporting	IMPACT Platform	1214 Hotline	Vaccination Sites/ Hospital Sites	MAH	Others <sup>§</sup>
Number of Case Reports	3,866	2,138	955	159	70
Percentage	53.8%	29.7%	13.3%	2.2%	1.0%

<sup>§</sup>MAH was included under others in report 10, due to the low number of received cases during that period.

Table 2 classifies the 7,188 reported cases according to their occurrence after the 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> dose of COVID-19 vaccines. 7,188 case reports, 5,339 case reports (74.28%) were after the 1<sup>st</sup> dose, 1,452 case reports (20.20%) were after the 2<sup>nd</sup> dose, (20.20%) were after the 3<sup>rd</sup> dose, and 7 case reports were after the 4th dose (0.10%). The remaining 87 case reports (1.21%) were missing the dose number.

**Table 2. Summary of case reports\* and AEFIs\*\* according to received dose**

	Total Doses		Dose 1		Dose 2		Dose 3		Dose 4	
	Case Reports (%)	AEFIs (%)	Case Reports (%)	AEFIs (%)	Case Reports (%)	AEFIs (%)	Case Reports (%)	AEFIs (%)	Case Reports (%)	AEFIs (%)
<b>All Vaccines Combined</b>										
<b>Pfizer–BioNTech</b>	4,573 (63.62)	14,100 (54.56)	3,018 (66.0)	8,678 (44.92)	1,204 (26.33)	4,460 (82.51)	273 (5.97)	822 (89.73)	7 (0.15)	18 (100)
<b>AstraZeneca</b>	2,314 (32.2)	10,543 (40.80)	2,127 (91.92)	9,894 (51.22)	170 (7.35)	585 (10.82)	2 (0.08)	9 (0.98)	0	0
<b>Sputnik V</b>	236 (3.28)	986 (3.81)	176 (74.46)	684 (3.54)	60 (25.54)	302 (5.58)	0	0	0	0
<b>Moderna</b>	49 (0.68)	154 (0.59)	8 (16.33)	22 (0.11)	12 (24.49)	40 (0.74)	28 (57.14)	85 (9.28)	0	0
<b>Sinopharm</b>	16 (0.22)	58 (0.22)	10 (62.5)	40 (0.21)	6 (37.5)	18 (0.33)	0	0	0	0
<b>Total</b>	7,188 (100)	25,841 (100)	5,339 (74.28)	19,318 (74.76)	1,452 (20.20)	5,405 (20.9)	303 (4.22)	916 (3.54)	7 (0.10)	18 (0.069)

\*87 case reports were missing the dose number (1.21%)

\*\* 184 AEFIs were missing dose number (0.71%)

Table 3 represents the distribution of the 7,188 reported cases and administered doses over the 8 governorates in Lebanon (Mount Lebanon, Beirut, North Lebanon, Bekaa, South Lebanon, Nabatiyeh, Akkar, and Baalbeck-Hermel) from February 14<sup>th</sup>, 2021, till December 14<sup>th</sup>, 2022. The geographical division of Lebanon and all the data pertaining to each governorate are retrieved from the IMPACT platform.

**Table 3. Summary of administered doses and case reports<sup>^</sup> per governorate**

Total	Total Dose Administered		Total Case Reports	
	5,602,239		7,188	
Governorates	Count	Percentage	Count	Percentage
Mount Lebanon <sup>*</sup>	2,166,034	38.66%	2,907	40.45%
Beirut <sup>**</sup>	888,217	15.85%	2,078	28.91%
North Lebanon <sup>†</sup>	665,450	11.88%	732	10.18%
South Lebanon <sup>‡</sup>	595,760	10.63%	406	5.64%
Bekaa <sup>§</sup>	437,942	7.82%	253	3.51%
Nabatiyeh <sup>¶</sup>	415,999	7.43%	213	2.96%
Akkar <sup>  </sup>	206,383	3.68%	143	2.0%
Baalbeck-Hermel <sup>‡</sup>	216,455	3.98%	97	1.35%

<sup>^</sup>359 case reports had the governorate section missing (5.0%)

<sup>\*</sup> A case report may include more than one AEFI

<sup>\*\*</sup>Mount Lebanon governorate includes vaccination centers in Aley, Baabda, Chouf, Matn, Jbeil, Keserwan, and Baskinta

<sup>†</sup>Beirut governorate includes vaccination centers in Beirut area

<sup>‡</sup>North Lebanon governorate includes vaccination centers in Batroun, Bcharreh, Koura, Minieh-Danniyeh, and Tripoli


<sup>§</sup>South Lebanon governorate includes vaccination centers in Jezzine, Saida, and Tyre

<sup>¶</sup>Bekaa governorate includes vaccination centers in Rashaya, West Bekaa, and Zahleh

<sup>||</sup>Nabatiyeh governorate includes vaccination centers in Bint Jbeil, Hasbaya, and Marjeyoun

<sup>‡</sup>Akkar governorate includes vaccination centers in Akkar

<sup>‡</sup>Baalbeck-Hermel governorate includes vaccination centers in Baalbeck and Hermel



359 cases were missing the governorates

**Figure 1. Summary of administered doses and case reports following Pfizer-BioNTech and AstraZeneca COVID-19 vaccines per governorate**

This figure presents the total doses administered and total number of case reports per governorate for Pfizer-BioNTech and AstraZeneca COVID-19 vaccines. The number of case reports received per governorate dropped as the number of doses administered decreased. The highest number of case reports were from Mount-Lebanon which was associated with the highest number of administered doses whereas in Nabatiyeh, for example, a lower number of case reports was received which may be attributed to the lower number of doses administered.


**Table 4. Summary of all case reports related to COVID-19 vaccines available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

	All Vaccines Combined	Pfizer-BioNTech	AstraZeneca	Sputnik V	Moderna	Sinopharm
Total Doses Administered	5,602,239	4,672,331	721,018	123,740	49,879	21,724
Total case reports (%)	7,188 (100)	4,573 (63.62)	2,314 (32.2)	236 (3.28)	49 (0.68)	16 (0.22)
Non serious case reports* (%)	6,654 (92.6)	4,198 (91.80)	2,172 (93.86)	226 (95.76)	46 (93.88)	12 (75.0)
Serious case reports** (%)	534 (7.4)	375 (8.20)	142 (6.14)	10 (4.24)	3 (6.12)	4 (25.0)
Total reporting rate per 1,000 doses administered	1.28	0.98	3.21	1.91	0.98	0.74
Serious reporting rate per 1,000 doses administered	0.1	0.08	0.20	0.08	0.06	0.18

Data Source: Vigilyze (Dataset date: 14/12/2022, MedDRA version: 24.1)

\* Non serious cases include expected local and systemic AEFIs resolved without the need for further follow up or investigation

\*\* Serious cases are those who meet the WHO seriousness criteria (refer to Technical Notes)



\*Numbers presented on the blue and red bars reflect the number of case reports reported by month

**Figure 2: Number of case reports\*, doses administered, non-serious and serious cases by month of the five COVID-19 Vaccines' administration in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**



Case reports are assessed based on the date of vaccine administration. The administration period ranges from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022. Accordingly, case reports were received as of February 14<sup>th</sup>, 2021, with an increase in both serious and non-serious case reports. The highest reporting rate was during the month of May 2021 for the non-serious cases and June 2021 for the serious cases.

## b. Demographics

Tables 5 and 6 present a summary of case reports related to the COVID-19 vaccines by age group, gender, and reporter qualification.

**Table 5. Summary of all case reports by age group and gender related to the five COVID-19 vaccines available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

Gender	COUNT	PERCENTAGE
Female	4,381	61.0%
Male	2,807	39.0%
Age		
2 – 11 years	3	0%
12– 17 years	266	3.7%
18 – 44 years	3,915	54.5%
45 – 64 years	2,075	28.9%
65 – 74 years	370	5.1%
≥ 75 years	433	6.0%
Unknown	126	1.8%

Data Source: VigilYZe (Dataset date: 14/12/2022, MedDRA version: 24.1)

Note: Age represents the age at time of vaccination. Some case reports may be missing the date of birth

**Table 6. Summary of all case reports by reporter qualification related to the five COVID-19 vaccines available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

Reporter Qualification	COUNT	PERCENTAGE
Physician	293	4.1%
Pharmacist	207	2.9%
Other Health Professional	719	10.0%
Consumer/Non-Health Professional	5,969	83.0%

Data Source: VigilYZe (Dataset date: 14/12/2022, MedDRA version: 24.1)



## c. Non serious Adverse Events Following Immunization

A case report refers to a report received by the PV Program, which pertains to one individual vaccine recipient who has reported at least one adverse event after receiving one of the COVID-19 vaccines (i.e., temporally associated with the vaccine).

The tables below give an overview of the top reported non-serious AEFIs.

### i. Most Reported Non-Serious AEFIs Related to COVID-19 Vaccines:

**Table 7. Top 15 AEFIs by reported Preferred Terms (PTs)\* related to the five COVID-19 vaccines available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

Reported Preferred Terms (MedDRA)	COUNT	PERCENTAGE
Injection site pain	2,824	39.2%
Fatigue	2,749	38.2%
Pain	2,690	37.3%
Headache	2,494	34.6%
Pyrexia	2,230	31.0%
Chills	2,017	28.0%
Nausea	1,110	15.4%
Injection site swelling	641	8.9%
Dyspnea	582	8.1%
Abdominal pain	495	6.9%
Diarrhea	485	6.7%
Dizziness	445	6.2%
Cough	427	5.9%
Injection site erythema	423	5.9%
Vomiting	391	5.4%

Data Source: Vigilyze (Dataset date: 14/12/2022, MedDRA version: 24.1).

\*Preferred Terms (PTs) are distinct descriptors (single medical concept) for a symptom, sign, disease diagnosis, therapeutic indication, investigation, surgical or medical procedure, and medical social or family history characteristic.

### ii. Non serious AEFIs per specific vaccine:

**Table 8. Top 10 AEFIs by reported Preferred Terms (PTs)\* related to the Pfizer-BioNTech COVID-19 vaccine available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

Reported Preferred Terms (MedDRA)	COUNT	PERCENTAGE
Injection site pain	1,492	35.5%
Pain	1,393	33.2%
Fatigue	1,281	30.5%
Headache	1,198	28.5%
Pyrexia	1,022	24.3%
Chills	902	21.5%
Nausea	511	12.2%
Injection site swelling	400	9.5%
Dyspnea	309	7.4%
Dizziness	273	6.5%

Data Source: Vigilyze (Dataset date: 14/12/2022, MedDRA version: 24.1).

\*Preferred Terms (PTs) are distinct descriptors (single medical concept) for a symptom, sign, disease diagnosis, therapeutic indication, investigation, surgical or medical procedure, and medical social or family history characteristic.

**Table 9. Top 10 AEFIs by reported Preferred Terms (PTs)\* related to the AstraZeneca COVID-19 vaccine available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

Reported Preferred Terms (MedDRA)	COUNT	PERCENTAGE
Fatigue	1,220	56.2%
Injection site pain	1,138	52.4%
Pain	1,101	50.7%
Headache	1,079	49.7%
Pyrexia	1,005	46.3%
Chills	926	42.6%
Nausea	495	22.8%
Abdominal pain	222	10.2%
Injection site swelling	203	9.3%
Dyspnea	197	9.1%

Data Source: VigilYZe (Dataset date: 14/12/2022, MedDRA version: 24.1).

\*Preferred Terms (PTs) are distinct descriptors (single medical concept) for a symptom, sign, disease diagnosis, therapeutic indication, investigation, surgical or medical procedure, and medical social or family history characteristic.

**Table 10. Top 10 AEFIs by reported Preferred Terms (PTs)\* related to the Sputnik V COVID-19 vaccine available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

Reported Preferred Terms (MedDRA)	COUNT	PERCENTAGE
Fatigue	150	66.4%
Pain	119	52.7%
Headache	112	49.6%
Chills	111	49.1%
Injection site pain	111	49.1%
Pyrexia	98	43.4%
Nausea	52	23.0%
Diarrhea	20	8.8%
Cough	16	7.1%
Dyspnea	15	6.6%

Data Source: VigilYZe (Dataset date: 14/12/2022, MedDRA version: 24.1).

\*Preferred Terms (PTs) are distinct descriptors (single medical concept) for a symptom, sign, disease diagnosis, therapeutic indication, investigation, surgical or medical procedure, and medical social or family history characteristic.

**Table 11. Top 10 AEFIs by reported Preferred Terms (PTs)\* related to the Moderna COVID-19 vaccine available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

Reported Preferred Terms (MedDRA)	COUNT	PERCENTAGE
Pain	17	37.0%
Headache	15	32.6%
Injection site pain	15	32.6%
Pyrexia	14	30.4%
Chills	11	23.9%
Fatigue	11	23.9%
Injection site swelling	6	13.0%
Dyspnea	4	8.7%
Myalgia	4	8.7%
Nausea	4	8.7%

Data Source: VigilYZe (Dataset date: 14/12/2022, MedDRA version: 24.1).

\*Preferred Terms (PTs) are distinct descriptors (single medical concept) for a symptom, sign, disease diagnosis, therapeutic indication, investigation, surgical or medical procedure, and medical social or family history characteristic.

**Table 12. Top 10 AEFIs by reported Preferred Terms (PTs)\* related to the Sinopharm COVID-19 vaccine available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

Reported Preferred Terms (MedDRA)	COUNT	PERCENTAGE
Fatigue	6	50.0%
Injection site pain	5	41.7%
Pain	3	25.0%
Nausea	3	25.0%
Chest pain	3	25.0%
Dyspnea	3	25.0%
Pyrexia	2	16.7%
Cough	2	16.7%
Dizziness	2	16.7%
Headache	2	16.7%

Data Source: Vigilyze (Dataset date: 14/12/2022, MedDRA version: 24.1).

\*Preferred Terms (PTs) are distinct descriptors (single medical concept) for a symptom, sign, disease diagnosis, therapeutic indication, investigation, surgical or medical procedure, and medical social or family history characteristic.



**Table 13. Summary of number and percentage of reported non-serious AEFIs by System Organ Class (SOC)\* related to the five COVID-19 vaccines available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

Reaction (MedDRA)	All Vaccines Combined (%)	Pfizer-BioNTech (%)	Astra Zeneca (%)	Sputnik V (%)	Moderna (%)	Sinopharm (%)
General disorders and administration site conditions	5,465 (82.1)	3,251 (77.4)	1,958 (90.1)	211 (93.4)	33 (71.7)	10 (83.3)
Nervous system disorders	2,968 (44.6)	1,596 (38.0)	1,225 (56.4)	120 (53.1)	21 (45.7)	5 (41.7)
Gastrointestinal disorders	1,723 (25.9)	886 (21.1)	751 (34.6)	70 (31.0)	13 (28.3)	3 (25.0)
Respiratory, thoracic and mediastinal disorders	805 (12.2)	512 (12.2)	262 (12.1)	20 (8.8)	7 (15.2)	3 (25.0)
Musculoskeletal and connective tissue disorders	726 (10.9)	426 (10.1)	268 (12.3)	17 (7.5)	14 (30.4)	1 (8.3)
Skin and subcutaneous tissue disorders	542 (8.1)	329 (7.8)	191 (8.8)	17 (7.5)	4 (8.7)	1 (8.3)
Vascular disorders	273 (4.1)	209 (5.0)	63 (2.9)	0	1 (2.2)	0
Cardiac disorders	177 (2.7)	131 (3.1)	45 (2.1)	0	1 (2.0)	0
Investigations**	145 (2.2)	102 (2.4)	41 (1.9)	0	1 (2.0)	1 (8.3)
Eye disorders	138 (2.1)	81 (1.9)	53 (2.4)	2 (0.9)	1 (2.2)	1 (8.3)
Infections and infestations	98 (1.5)	71 (1.7)	22 (1.0)	3 (1.3)	0	1 (8.3)
Blood and lymphatic system disorders	95 (1.4)	83 (2.0)	9 (0.4)	2 (0.9)	1 (2.2)	0
Ear and labyrinth disorders	68 (1.0)	48 (1.1)	16 (0.7)	4 (1.8)	0	0
Injury, poisoning and procedural complications	52 (0.8)	29 (0.7)	22 (1.0)	0	1 (2.2)	0
Immune system disorders	41 (0.6)	26 (0.6)	13 (0.6)	0	2 (4.3)	0
Reproductive system and breast disorders	49 (0.7)	28 (0.7)	20 (0.9)	1 (0.4)	0	0
Psychiatric disorders	42 (0.6)	20 (0.5)	22 (1.0)	0	0	0
Metabolism and nutrition disorders	38 (0.6)	15 (0.4)	22 (1.0)	0	1 (2.2)	0
Renal and urinary disorders	14 (0.2)	8 (0.2)	6 (0.3)	0	0	0
Surgical and medical procedures	4 (0.1)	4 (0.1)	0	0	0	0
Endocrine disorders	2 (0.0)	2 (0.0)	(0.0)	0	0	0
Neoplasms benign, malignant, and unspecified (incl cysts and polyps)	2 (0.0)	2 (0.0)	0	0	0	0
Product issues	1 (0.0)	1 (0.0)	0	0	0	0

Data Source: Vigilyze (Dataset date: 14/12/2022, MedDRA version: 24.1)

\*System Organ Classes (SOCs) are groupings by etiology (e.g., Infections and infestations), manifestation site (e.g., Gastrointestinal disorders) or purpose (e.g., surgical and medical procedures)

\*\* Investigations include cases of abnormal blood pressure, increased blood pressure, decreased blood pressure, increased systolic blood pressure, increased heart rate, irregular heart rate, increased Fibrin D-Dimer, decreased weight, decreased oxygen saturation, increased blood glucose levels, decreased blood iron, increased blood pH, increased intraocular pressure, red blood cells in urine, decreased urine output, and cases who tested positive or negative for SARS-CoV-2.


## d. Serious Adverse Events Following Immunization

According to the WHO, a serious AEFI is an event that results in death, hospitalization, or prolongation of an existing hospitalization, persistent or significant disability or incapacity, congenital anomaly/birth defect or is life-threatening. The ICH E2A and E2D Guidelines (refer to Technical Notes) have also stated that other situations such as other medically important event or reaction which may jeopardize the patient or may require intervention to prevent one of the outcomes stated in the serious case definition, should also be considered serious after applying medical and scientific judgment. Those “other situations” are open to interpretation and could vary from jurisdiction to jurisdiction. In this report, serious case reports following immunization were classified as follows:

- **Other Medically Important Events** : This includes unexpected AEFIs, local or systemic, that may be serious in their nature but did not require hospitalization nor resulted in death. They may include ER visits and may or may not be resolved in the next 48 hours. These case reports are followed by the PV team over the phone without further investigation.
- **Serious Cases** : This includes cases that resulted in death, hospitalization, disability, congenital abnormalities, or were life threatening. These are investigated and evaluated for causality assessment.

534 case reports included serious AEFIs as per the WHO definition, out of which 391 case reports did not require hospitalization nor lead to death. These were identified as other medically important events. 143 case reports were serious cases that were either admitted to the hospital or resulted in death (Figure 3).

Out of the 143 cases mentioned above, 64 case reports fit the WHO definition of seriousness criteria, but they did not require on-site investigations and they were followed up by phone only; 80 cases were serious reports that required full investigation. A total of 79 serious cases have been completed with a final decision by the Serious AEFI Special Committee at the Ministry of Public Health.



\*As per the WHO definition (refer to Technical Notes for serious cases definition as per WHO)

**Figure 3. Classification of case reports by seriousness criteria\* related to the five COVID-19 vaccines available in Lebanon, from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

**Table 14. Summary of the 79 serious case reports that have been completed with a final decision by the Serious AEFI Special Committee****i. Per Vaccine Type**

	All Cases	Pfizer-BioNTech	AstraZeneca	Sinopharm
Number of case report (%)	79 (100)	64 (81.0)	14 (17.7)	1 (1.3)
<b>Age (years)</b>				
12 - 17 years	3	3	0	0
18 - 44 years	13	8	4	1
45 - 64 years	23	14	9	0
65 - 74 years	13	12	1	0
≥ 75 years	27	27	0	0
Median Age in years (range)	61.86 (12-95)	64.86 (12-95)	49.71 (29-65)	43
<b>Gender (%)</b>				
Male	40 (50.6)	33 (51.6)	7 (50.0)	0
Female	39 (49.4)	31 (48.4)	7 (50.0)	1 (100)
<b>Dose number (%)</b>				
1 <sup>st</sup>	46 (58.2)	34 (53.1)	11 (78.57)	1 (100)
2 <sup>nd</sup>	26 (32.9)	24 (37.5)	2 (14.29)	0
3 <sup>rd</sup>	6 (7.6)	6 (9.4)	0	0
1 <sup>st</sup> and 2 <sup>nd</sup> *	1 (1.3)	0	1 (7.14)	0
Median TTO in days (range)**	7 (0-93)	4 (0-93)	7 (2-32)	20
<b>Median TTO in days (range) per dose</b>				
1 <sup>st</sup>	5 (0-32)	5 (0-26)	7 (2-32)	20
2 <sup>nd</sup>	3 (0-93)	3 (0-93)	3.5 (2-5)	0
3 <sup>rd</sup>	4 (0-44)	4 (0-44)	0	0
1 <sup>st</sup> and 2 <sup>nd</sup> *	9	0	9	0
<b>Mean TTO in days (SD) per dose***</b>				
1 <sup>st</sup>	8.54 (7.85)	7.41 (7.19)	11 (9.11)	20
2 <sup>nd</sup>	10.19 (18.93)	10.75 (19.62)	3.5 (2.12)	0
3 <sup>rd</sup>	12.17 (17.54)	12.17 (17.54)	0	0
1 <sup>st</sup> and 2 <sup>nd</sup> *	9	0	9	0
<b>Seriousness Criteria (%)</b>				
Fatal	22 (27.85)	17 (26.56)	4 (28.57)	1 (100)
Hospitalized	57 (72.15)	47 (73.44)	10 (71.43)	0
<b>AEFI Committee Decision (%)</b>				
Coincidental	41 (51.90)	35 (54.69)	5 (35.71)	1 (100)
Indeterminate	25 (31.65)	20 (31.25)	5 (35.71)	0
Consistent	13 (16.45)	9 (14.06)	4 (28.58)	0

\* This is an immunization-error case in which the patient received both doses during the same vaccination session

\*\* TTO: Time to onset

\*\*\* SD: Standard deviation

## ii. Per Seriousness Criteria

Completed Serious Cases	Total (N=79)	Hospitalized Case Reports (N=57)	Fatal Case Reports (N=22)
<b>Gender (%)</b>			
Males	40 (50.6)	28 (49.12)	12 (54.55)
Females	39 (49.4)	29 (50.88)	10 (45.45)
<b>Age Range (years)</b>			
	12 – 95	12 – 95	29 – 92
<b>Dose Received (%)</b>			
Dose 1	46 (58.23)	34 (59.65)	12 (54.55)
Dose 2	26 (32.91)	17 (29.83)	9 (40.9)
Dose 3	6 (7.60)	5 (8.77)	1 (4.55)
Dose 1 and 2	1 (1.26)	1 (1.75)	0
<b>Time to Onset (days)</b>			
	0 – 93	0 – 44	0 – 93
<b>AEFI Committee Decision (%)</b>			
Coincidental	41 (51.90)	29 (50.88)	12 (54.55)
Indeterminate	25 (31.65)	17 (29.82)	8 (36.36)
Consistent	13 (16.45)	11 (19.30)	2 (9.09)

Table 15. Summary of reported AEFIs for the 79 completed serious cases by System Organ Class (SOC)

Vaccine Brand \ SOC	Total (N=79)	Pfizer–BioNTech (N=64)	AstraZeneca (N=14)	Sinopharm (N=1)
Cardiovascular disorders*	50	41	9	0
Nervous system disorders**	11	9	2	0
Infections and infestations***	8	7	1	0
Immune system disorders <sup>¶</sup>	5	5	0	0
Respiratory, thoracic, and mediastinal disorders <sup>^</sup>	3	2	0	1
Blood and lymphatic system disorders <sup>°</sup>	1	0	1	0
Surgical and medical procedures <sup>§</sup>	1	0	1	0

\* Includes case reports of ischemic heart disease, cardiac arrest, cerebrovascular accidents, myocardial infarction, myocarditis, pericarditis, atrial fibrillation, extensive portal vein thrombosis, unstable angina, Kounis Syndrome, and thrombotic disorders

\*\* Includes case reports of Guillain-Barré Syndrome, acute disseminated encephalomyelitis, Amyotrophic Lateral Sclerosis, cerebral hemorrhage, functional neurological dysfunction, epilepsy, and optic neuritis

\*\*\* Includes case reports of pneumonia, acute bronchitis, and sepsis

<sup>¶</sup> Includes case reports of acute severe urticaria, anaphylactic shock, psoriasis exacerbation, autoimmune hemolytic anemia, and hyperstimulation of the immune system

<sup>^</sup> Includes case reports of dyspnea, polypnea, and pulmonary edema

<sup>°</sup> Includes case reports febrile neutropenia and Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)

<sup>§</sup> Includes case reports of post-surgical bleeding

## e. Adverse Events Following Immunization in Pregnant Women

Between February 14<sup>th</sup>, 2021, and December 14<sup>th</sup>, 2022, 7 case reports were reported among pregnant women in Lebanon. Out of these 7 case reports, 5 were following Pfizer-BioNTech vaccine and the remaining 2 were following the AstraZeneca vaccine. All 7 case reports included non-serious AEFIs such as injection site pain, fever, and chills. Table 16 summarizes these 7 case reports.



**Table 16. Summary of case reports following COVID-19 vaccines reported in pregnant women in Lebanon from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022**

Pregnant Women	All Cases	Pfizer-BioNTech	AstraZeneca
Number of case report (%)	7 (100)	5 (71.4)	2 (28.6)
Age (Mean ± SD)*	33.57 ± 4.72	32 ± 4.42	37.5 ± 3.54
<b>Dose number (%)</b>			
1 <sup>st</sup>	4 (57.15)	2 (40)	2 (100)
2 <sup>nd</sup>	2 (28.57)	2 (40)	0
3 <sup>rd</sup>	1 (14.28)	1 (40)	0
<b>TTO** in days per dose (Mean ± SD)</b>			
1 <sup>st</sup>	2.71 ± 5.9	8 ± 11.3	0
2 <sup>nd</sup>	1.5 ± 0.7	1.5 ± 0.7	--
3 <sup>rd</sup>	0	0	--

\*SD: Standard deviation

\*\*TTO: Time to onset



## **f. Adverse Events Following Immunization in Children and Adolescents**

Between February 14<sup>th</sup>, 2021, and December 14<sup>th</sup>, 2022, 266 cases were reported by adolescents aging between 12 and 17 years old. Out of the 266 cases, 247 were non-serious (Table 17, i). A total of 19 serious cases were identified as per the WHO definition. Out of the 19 serious cases, 16 did not require on-site investigation and were followed up by phone only, and the remaining 3 cases that were admitted to the hospital required investigation and causality assessment.

Three non-serious cases have been reported in children aging between 5 and 11. The reactions are presented in (Table 17, ii).

**Table 17. Summary of non-serious case reports following COVID-19 vaccines reported in adolescents and in children in Lebanon from February 14<sup>th</sup>, 2021, to December 14<sup>th</sup>, 2022****i. In Adolescents<sup>o</sup>:**

		All vaccines combined	Pfizer–BioNTech	Moderna	1 (100)
Gender	Male	140 (52.6)	139 (52.7)	0	0
	Female	126 (47.4)	123 (47.3)	3 (100)	92
Total doses administered (%)		387,214	386,706	416	1 (0.4)
Number of case reports (%)		266 (100)	262 (98.5)	3 (1.1)	1 (0.4)
Number of non-serious case reports (%)		247 (92.85)	243 (98.38)	3 (1.22)	1
Number of non-serious AEFIs		727	717	9	
<b>Top 10 non-serious AEFIs N (%)</b>					
Pyrexia		69 (27.9)			
Injection site pain		66 (26.7)			
Headache		62 (25.1)			
Fatigue		60 (24.3)			
Dizziness		41 (16.6)			
Hypotension		40 (16.2)			
Pain		43 (16.2)			
Chills		33 (12.4)			
Nausea		29 (10.9)			
Abdominal pain		23 (8.6)			

<sup>o</sup> Adolescents include the age group of 12 to 17 years' old**ii. In Children<sup>o</sup>:**

		Pfizer–BioNTech
Gender	Male	2 (66.7)
	Female	1 (33.3)
Total doses administered (%)		34,016
Number of case reports (%)		3 (100)
Number of non-serious case reports (%)		3 (100)
Number of non-serious AEFIs		5
<b>Top non-serious AEFIs N (%)</b>		
Hypotension		2 (66.7)
Syncope		2 (66.7)
Dizziness		1 (33.33)

<sup>o</sup> Children include the age group of 5 to 11 years' old**g. Safety Signals**

The PV team has adopted two sources for identifying signals (refer to Technical Notes) associated with AEFIs with Pfizer–BioNTech and AstraZeneca COVID-19 Vaccine: The French National Security Agency of Medicines and Health Products (ANSM) and the World Health Organization–Uppsala Monitoring Center (WHO–UMC) Classification.

Tables 18 and 19 summarize the reported AEFIs in Lebanon during the time of this report which may be either potential or confirmed signals for Pfizer–BioNTech and AstraZeneca COVID-19 vaccines according to the ANSM reports and/or the WHO-UMC Vigibase.

**Table 18. Confirmed signals identified in Lebanon**

Pfizer–BioNTech		AstraZeneca	
Safety Signal	Count	Safety Signal	Count
Arterial Hypertension†	150	Flu-Like Syndrome	33
Tinnitus	12	Tinnitus	8
Trigeminal Neuralgia§	4	Photophobia	3
Pericarditis	3	Thrombosis Associated with Thrombocytopenia	2
Myocarditis	2	Trigeminal Neuralgia§	1
Photophobia	1	Deafness	1
Deafness	1	Facial Paralysis	1
Corneal Transplant Rejection	1		
Subacute Thyroiditis	2		

Data Source: Vigilyze (Dataset date: 14/12/2022, MedDRA version: 24.1).

Data Source: ANSM (03/12/2022)

Data Source: World Health Organization–Uppsala Monitoring Center (WHO-UMC)

†Cases of arterial hypertension included the terms: blood pressure abnormal, blood pressure systolic increase, blood pressure increased, hypertension, hypertensive crisis, and hypertensive emergency.

§Cases of trigeminal neuralgia included the term: facial paralysis

**Table 19. Potential signals identified in Lebanon**

Pfizer–BioNTech		AstraZeneca	
Safety Signal	Count	Safety Signal	Count
Cardiac Rhythm Disorders§	196	Erythema nodosum#	179
Menstrual Irregularities <sup>  </sup>	21	Arrhythmias§	71
Cerebral Vein Thrombosis‡	19	Elevated Blood Pressure¶	56
Shingles†	12	Mucocutaneous Bleeding**	45
Vaccination Failure††	15	Venous and arterial thromboembolic event^	13
Pancreatitis	1	Pancreatitis	2
Rheumatoid arthritis	1	Myocardial Infarction	1

Data Source: Vigilyze (Dataset date: 14/12/2022, MedDRA version: 24.1).

Data Source: ANSM (03/12/2022)

§Cases of cardiac rhythm disorders and arrhythmias included the terms: tachycardia, palpitations, bradycardia, cardiac arrest, increased heart rate, arrhythmia, sinus bradycardia, Atrial fibrillation, and irregular heart rate

||Cases of menstrual irregularities included the terms: menstruation irregular, menstruation delayed, menstrual disorder, vaginal hemorrhage, heavy menstrual bleeding,

‡Cases of cerebral vein thrombosis included the terms: ischemic stroke, ischemic cerebral infarction, cerebral ischemia, and transient ischemic attack

†Cases of shingles included the terms: herpes zoster

††Cases of vaccination failure included the terms: vaccination failure, drug ineffective

#Cases of erythema nodosum included the terms: rash erythematous, injection site erythema, and erythema

\*\*Cases of mucocutaneous bleeding included the terms: contusion, injection site bruising, epistaxis, and oral contusion

¶Cases of elevated blood pressure included the terms: blood pressure abnormal, blood pressure systolic increase, blood pressure increased, hypertension, hypertensive crisis, and hypertensive emergency

^Cases of venous and arterial thromboembolic event the terms: deep vein thrombosis, thrombosis, axillary vein thrombosis, portal vein thrombosis

# DESCRIPTION OF SERIOUS ADVERSE EVENTS FOLLOWING IMMUNIZATION

## ***AEFIs requiring Hospitalization or with Fatal Outcome (Tables 14 and 15)***

AEFIs are classified as serious according to the seriousness criteria of WHO (refer to the Technical Notes). These cases either require a phone call only or an investigation followed by a causality assessment to evaluate the potential relationship between the AEFI and the vaccine and to implement the appropriate follow-up actions. The investigation is carried out by the PV team members. It includes an extensive and rigorous scientific evaluation based on available information about the vaccination site, the patient's medical records, laboratory results, and information retrieved from the recipient or his/her relatives. After collecting all the available information, the investigation report is filled, and a causality assessment is performed by a group of experts to review the potential causal association between the AEFI and the vaccine. WHO forms and tools are used to carry out both the investigation and the causality assessment. Findings are discussed with the Serious AEFI Special Committee at the Ministry of Public Health. In the period of time covered by this report, there were 143 case reports classified as serious per the WHO-UMC definition that resulted in either hospitalization or death, representing 1.98% of all case reports and a reporting rate 0.026 per 1,000 doses of vaccines.

## ***Overview of completed serious case reports (Tables 14 and 15)***

Out of the 79 serious case reports that were completed with a final decision by the Serious AEFI Special Committee, there are 57 cases of hospitalization and 22 cases of death temporally associated with the receipt of the COVID-19 vaccine.

For the 57 suspected hospitalization cases post vaccination (28 Males, 29 Females), the vaccine recipients' age range was between 12 and 95 years old. A total of 45 hospitalizations occurred after the first dose, 26 hospitalizations occurred after the second dose, while the remaining 6 hospitalizations occurred after the third dose. There is one case of immunization error where the patient received both doses during the same vaccination session. The 57 vaccine recipients experienced AEFIs within few minutes to 44 days' post-vaccination. The Serious AEFI Special Committee at the Ministry of Public Health confirmed the coincidental causality assessment in 29 case reports. 17 were considered as indeterminate, and 11 case reports were classified as consistent: 1 case of MI, 1 case of anaphylactic shock, 2 cases of Guillain-Barré Syndrome, 1 case of myocarditis, 1 case of pericarditis, 2 cases of ischemic CVA, 1 case of atopic dermatitis, 1 case of autoimmune hemolytic anemia, and 1 case of functional neurological disorder.

In the 22 suspected cases of death post vaccination (12 Males, 10 Females), the vaccine recipients' age range was between 29 and 92 years old. A total of 12 death cases were after the first dose, 9 were after the second dose, and the remaining case was after the third dose. The 22 vaccine recipients experienced AEFIs within 30 minutes to 93 days' post-vaccination. The Serious AEFI Special Committee at the MoPH confirmed the coincidental classification in 12 case reports, 8 case reports were considered as indeterminate, and 2 case reports showed a consistent association due to the lack of other clearly attributing factors.

# COMPARISON OF AEFIS WITH COVID-19 VACCINES IN LEBANON WITH INTERNATIONAL DATA

## a. Ontario, Canada Based on the Public Health Ontario

Based on the weekly surveillance summary published by Public Health Ontario (PHO) regarding AEFI for COVID-19 in Ontario, covering the period between December 13<sup>th</sup>, 2020, to November 20<sup>th</sup>, 2022, 1,208 case reports have been classified as serious, representing 5.5% of the total AEFI reports and a serious AEFI reporting rate of 0.033 per 1,000 doses administered for all vaccine products combined. Of the 1,208 reports, 1,177 reports required hospital admission related to the adverse event and 31 were reports of death. To note, 689 serious cases were reported following Pfizer-BioNTech COVID-19 vaccine, which represented a reporting rate of 0.02 per 1,000 doses administered, and 131 serious cases were reported following AstraZeneca COVID-19 vaccine, which represents a reporting rate of 0.004 per 1,000 doses administered (Tables 20, 21, and 22).

**Table 20. Case reports following COVID-19 vaccines in Lebanon in comparison with Ontario**

	Lebanon Feb 14, 2021 – December 14, 2022	Ontario Dec 30, 2021 – November 20, 2022
	All Vaccines Combined*	All Vaccines Combined**
Total Doses Administered	5,602,239	36,239,176
Total Case Reports	7,188	22,069
Non-serious Case Reports (%)	6,654 (92.57)	20,861 (94.5)
Serious Case Reports (%)	534 (7.43)	1,208 (5.5)
Total Reporting Rate per 1,000 Doses Administered	1.28	0.61
Serious Reporting Rate per 1,000 Doses Administered	0.095	0.033

\*Pfizer-BioNTech, AstraZeneca, Sputnik V, Sinopharm, and Moderna

\*\*Pfizer-BioNTech, Moderna, AstraZeneca, and Johnson & Johnson

**Table 21. Case reports following Pfizer-BioNTech COVID-19 vaccine in Lebanon in comparison with Ontario**

	Lebanon Feb 14, 2021 – December 14, 2022	Ontario Dec 30, 2021 – November 20, 2022
	Pfizer-BioNTech	Pfizer-BioNTech
Total Doses Administered	4,672,331	23,560,182
Total Case Reports	4,573	13,265
Non-serious Case Reports (%)	4,198 (91.80)	12,576 (94.8)
Serious Case Reports (%)	375 (8.2)	689 (5.2)
Total Reporting Rate per 1,000 Doses Administered	0.98	0.56
Serious Reporting Rate per 1,000 Doses Administered	0.08	0.029

**Table 22. Case reports following AstraZeneca COVID-19 vaccine in Lebanon in comparison with Ontario**

	Lebanon Feb 14, 2021 – December 14, 2022	Ontario Dec 30, 2021 – November 20, 2022
	AstraZeneca	AstraZeneca
Total Doses Administered	721,018	1,087,686
Total Case Reports	2,314	1,682
Non-serious Case Reports (%)	2,172 (93.86)	1,551 (92.21)
Serious Case Reports (%)	142 (6.14)	131 (7.79)
Total Reporting Rate per 1,000 Doses Administered	3.01	1.55
Serious Reporting Rate per 1,000 Doses Administered	0.20	0.12

## **b. United-States of America based on the Centers for Disease Control and Prevention**

According to the CDC, death reports after COVID-19 vaccination are rare. From December 14<sup>th</sup>, 2020, to November 24<sup>th</sup>, 2022, more than 655 million doses of COVID-19 vaccines were administered in the United States. Vaccine Adverse Event Reporting System (VAERS) received 17,640 preliminary death reports among people who received a COVID-19 vaccine (Table 23).

**Table 23. Reports of death following COVID-19 vaccines in comparison with the United States according to the Centers for Disease Control and Prevention (CDC)**

	Lebanon Feb 14, 2021 – December 14, 2022	United States of America Dec 14, 2020 – November 24, 2022
	All Vaccines Combined <sup>*</sup>	All Vaccines Combined <sup>**</sup>
Total Doses Administered	5,602,239	655,280,140
Preliminary Reports of Death <sup>^</sup>	22	17,640
Death Reporting Rate per 1000 doses	0.004	0.027

<sup>\*</sup> Pfizer-BioNTech, AstraZeneca, Sputnik V, Sinopharm, and Moderna

<sup>\*\*</sup> Pfizer-BioNTech, Moderna, Johnson & Johnson

<sup>^</sup> Reports of death do not necessarily mean that they are caused by the vaccine

## CONCLUSION

In Lebanon, from January 3<sup>rd</sup>, 2020, to December 14<sup>th</sup>, 2022, there have been approximately 1.22 million of confirmed SARS-CoV-2 cases with 10,740 deaths declared to the MoPH. Vaccination is the single and most effective way to reduce deaths and hospitalizations from COVID-19. The national immunization campaign was first deployed on February 14<sup>th</sup>, 2021. Pfizer-BioNTech is the only COVID-19 vaccine available currently. AstraZeneca, Sputnik V, Sinopharm, and Moderna are no longer available which explains the stability in the number of their case reports.

In this report, 92.6% of the cases reported were classified as non-serious, and 7.4% were classified as serious. It is important to note that reports of adverse events following vaccination, including hospitalizations and deaths, do not necessarily mean that they are related to the vaccine.

The PV Program at the Ministry of Public Health continues to conduct constant monitoring for the safety of COVID-19 vaccines in collaboration with its partners, including individual case review, daily analysis of surveillance data for vaccine safety signals, and regular reporting.

## TECHNICAL NOTES

- Important Medical Event Terms List: The EudraVigilance Expert Working Group (EV-EWG) has coordinated the development of an Important Medical Event Terms (IME, MedDRA version: 24.0) list. This IME list aims to facilitate the classification of suspected adverse reactions as well as aggregated data analysis and case assessment in the frame of the day-to-day PV activities of stakeholders. The IME list is intended for guidance purposes only.
- EudraVigilance is the system for managing and analyzing information on suspected adverse reactions to medicines which have been authorized or being studied in clinical trials in the European Economic Area (EEA). The European Medicines Agency (EMA) operates the system on behalf of the European Union (EU) medicines regulatory network.
- MedDRA (Medical Dictionary for Regulatory Activities) is a standardized medical terminology, published by the International Council for Harmonization, used for coding cases of adverse effects in clinical study reports and pharmacovigilance databases, and to facilitate searches in these databases.
- PIDM: The WHO Program for International Drug Monitoring (PIDM), established in 1968, provides a forum for WHO Member States to collaborate in the monitoring of drug safety, and notably, the identification and analysis of new adverse reaction signals from data submitted to the WHO global individual case safety report (ICSR) database by member countries.

- Seriousness Criteria: According to the WHO, a serious AEFI is an event that results in death, hospitalization, or prolongation of an existing hospitalization, persistent or significant disability or incapacity, congenital anomaly/birth defect or is life-threatening.
- ICH E2A Guidelines: Aims to develop standard definitions and terminology for key aspects of clinical safety reporting. It also provides guidance on the appropriate mechanism for handling expedited (rapid) reporting, in the investigational (i.e., pre-approval) phase.
- Safety Signal: According to the World Health Organization (WHO), a "signal" is a reported information on a possible causal relationship between an AE and a drug, the relationship being unknown or incompletely documented previously. Usually more than one report is required to generate a signal, depending on the seriousness of the event and the quality of the information.
- Trigeminal Neuralgia: is a neuropathic pain condition affecting the fifth cranial nerve and causing one of the most severe pains to be experienced. Symptoms include extreme, sporadic, sudden burning or shock like pain lasting from seconds up to two minutes and is usually unilateral.
- Myocarditis: An inflammation of the heart muscle (myocardium). Common myocarditis signs and symptoms include chest pain, rapid or abnormal heartbeat (arrhythmias), shortness of breath, or fluid buildup with leg swelling.
- Photophobia: Abnormal light sensitivity. It can occur as a symptom of various condition such as migraine headache or ophthalmic inflammation.
- Subacute thyroiditis: is a typically painful inflammatory condition of the thyroid, potentially causing hypothyroidism-like symptoms such as tachycardia, agitation, tremor, and hyperhidrosis.
- Corneal graft rejection: may occur at any time after transplant and can be caused by illness or injury of unknown cause. Typical symptoms include loss of vision, eye pain, red eyes and sensitivity to light with clinical signs including corneal edema, vascularization and precipitates.
- VigiFlow is a web-based individual case safety report (ICSR) management system that is available for use by national PV centers of the WHO Program for International Drug Monitoring.
- VigiBase is the WHO global ICSR database that contains ICSRs submitted by the participating member states enrolled under WHO's international drug monitoring program. It is the single largest drug safety data repository in the world.
- VigiLyze supports the collection, processing, and sharing of data of case reports to facilitate effective data analysis. VigiLyze is a signal detection and management system that can use national, regional, or global data as the starting point for quantitative signal detection.



## DATA CAVEATS

- Each case report refers to a reporter who reported an AEFI after receiving a dose of COVID-19 vaccine. A case report may contain multiple AEFIs. Therefore, the total number of AEFIs can exceed the number of individual case reports reported in a given time frame. Case reports that did not contain an AEFI at the time of data extraction or was missing the Vaccine name have been excluded.
- AEFI reporting rates were calculated using the number of vaccines' specific AEFIs reported in the specified time period in Lebanon divided by the doses of vaccines administered in the same time period in Lebanon.
- The information available in this report does not represent Uppsala Monitoring Center (UMC) nor WHO's opinions

## DISCLAIMER:

This document was developed by the Pharmacovigilance Program at the MoPH. The application and use of this document are the responsibility of the user. This document may be reproduced without the permission for non-commercial purposes **ONLY** and provided that the appropriate credit is given to the Pharmacovigilance Program at the MoPH. No changes and or modifications may be made to this document without the express of written permission from the PV program at the MoPH.

## CITATION:

Ministry of Public Health – Quality Assurance of Pharmaceutical Products – Pharmacovigilance Program (2022). Adverse Events Following Immunization for COVID-19 Vaccines in Lebanon: February 14<sup>th</sup>, 2021 to December 14<sup>th</sup>, 2022; Beirut, Lebanon.

## FOR FURTHER INFORMATION:

For further information, contact us via email: [pv@moph.gov.lb](mailto:pv@moph.gov.lb)

## BIBLIOGRAPHY

- ANSM. (2022). Point de situation sur la surveillance des vaccins contre la Covid-19 – Période du 12/11/2021 au 03/12/2022. <https://ansm.sante.fr/actualites/point-de-situation-sur-la-surveillance-des-vaccins-contre-la-covid-19-periode-du-12-11-2021-au-25-11-2021>

- Vigibase, Analysis of Reports in the WHO Global Database of Individual Case Safety Reports. <https://vigilyze.who-umc.org/>
- Centers for Disease Control and Prevention. (2022). Selected Adverse Events Reported after COVID-19 Vaccination. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/adverse-events.html>
- Centers for Disease Control and Prevention. (2022). Safety of COVID-19 Vaccines. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/safety-of-vaccines.html>
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). (1994). Guidelines for Clinical Safety assessment (E2a-e). [https://database.ich.org/sites/default/files/E2A\\_Guideline.pdf](https://database.ich.org/sites/default/files/E2A_Guideline.pdf)
- Lebanese Ministry of Public Health. (2021). Pharmacovigilance Department: Ministerial Decision related to Serious Adverse Events Following Immunization (AEFIs) Special Committee. <https://www.MoPH.gov.lb/userfiles/files/Laws%26Regulations/Karar%20603-2021.pdf>
- World Health Organization. (2022). Lebanon: WHO Coronavirus Disease (COVID-19) Dashboard with Vaccination Data. <https://covid19.who.int/region/emro/country/lb>
- Public Health Ontario. (2022). Adverse Events Following Immunization (AEFIs) for COVID-19 in Ontario: December 13, 2020 to November 20, 2022. [https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-aefi-report.pdf?sc\\_lang=en](https://www.publichealthontario.ca/-/media/documents/ncov/epi/covid-19-aefi-report.pdf?sc_lang=en)
- Monitoring of COVID-19 Infection in Lebanon December 5, 2022. COVID-19 Coronavirus Lebanon Cases (moph.gov.lb)
- VigiBase, the WHO global database of individual case safety reports
- World Health Organization. (2016). Global manual on surveillance of adverse events following immunization. <https://www.who.int/publications/i/item/10665206144>
- World Health Organization. (2020). Covid-19 vaccines: safety surveillance manual. <https://www.who.int/publications/i/item/9789240032781>

